Brief: Alkem Laboratories, Biosergen AB Enter Agreement For Development Of Novel Polyene Macrolide Antifungal Product
25/09/2023 06:02
Sept 25 (Reuters) - Alkem Laboratories Ltd ALKE.NS :
* ALKEM LABORATORIES LTD- COMPANY AND BIOSERGEN AB HAVE
ENTERED
INTO A CO-DEVELOPMENT AND LICENSE AGREEMENT
* ALKEM LABORATORIES LTD - WILL INVEST IN CLINICAL
DEVELOPMENT OF
BSG005 AND WILL BE GRANTED AN EXCLUSIVE LICENSE TO MARKET IT IN
INDIA
* ALKEM LABORATORIES LTD - AGREEMENT FOR DEVELOPMENT AND
COMMERCIALIZATION OF BIOSERGEN'S NOVEL POLYENE MACROLIDE
ANTIFUNGAL PRODUCT BSG005
* ALKEM WILL MANAGE FIRST CLINICAL PATIENT TRIAL
Source text for Eikon: ID:nBSE7yb9PV
Further company coverage: ALKE.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alkem Laboratories
See all newsBrief: Alkem Labs Approved Initiation Of Forensic Audit In Connection With Recent Incident Involving Alleged Misappropriation Of Funds By A Former Employee
Brief: Alkem Labs Launches Neuceno (Cenobamate) For Treatment Of Partial-Onset Seizures In Adult Patients
Brief: Alkem Labs Launches Renocia Exo, Ginsenoside Exosome-Based Hair Growth Serum
Brief: Alkem Labs Board Approves Investment Of Up To 750 Million Rupees For New Block At Baddi Manufacturing Facility
Brief: Alkem Laboratories Q1 Consol Revenue From Operations 37.4 Billion Rupees